Hemab Therapeutics (COAG) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.34 billion vs $1.24 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | ORIC |
|---|---|---|
| Share price | $28.70 | $12.01 |
| Market cap | $1.34B | $1.24B |
| 1-day change | +1.16% | +0.25% |
| YTD return | — | +46.82% |
| 1-year return | — | -14.94% |
| 5-year return | — | -26.00% |
| EPS (TTM) | $-4.33 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $14.68 |
| 52-week low | $23.00 | $7.23 |
| Distance from 52-week high | -48.21% | -18.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +113.24% | +78.43% |
| Average volume | 455.19K | 1.47M |
| Shares outstanding | 46.71M | 103.65M |
| Employees | 59 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
COAG vs ORIC FAQ
Which is bigger, Hemab Therapeutics or Oric Pharmaceuticals?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.34B compared with $1.24B for Oric Pharmaceuticals (ORIC).
Are Hemab Therapeutics and Oric Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Hemab Therapeutics and Biotechnology: Pharmaceutical Preparations for Oric Pharmaceuticals.